About Chugai
Chugai’s mission is
to create innovative drugs
for the benefit of patients.
News ReleasesRSS
- Oct 17, 2024 Verastem Oncology’s Announcement Regarding Avutometinib (Presentation of Updated RAMP 201 Data in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society)
- Oct 15, 2024 Roche Announces New Two-Year Data of Evrysdi for Children with Spinal Muscular Atrophy (SMA)
- Sep 25, 2024 Galderma’s Announcement Regarding Nemolizumab (Data Presentation at European Academy of Dermatology and Venereology)
- Sep 24, 2024 Anti-CD20 Monoclonal Antibody Rituxan® Approved for Treatment of Refractory Steroid-Resistant Nephrotic Syndrome
- Sep 24, 2024 Chugai Receives Approvals for Additional Indication of Evrysdi in Pre-Symptomatic Spinal Muscular Atrophy (SMA) and Additional Dosage for SMA Infants Under 2 Months of Age